Showing results (71-80 of 93) with videos related to

Sort By:
Pageof 10
Journal of Medicinal Chemistry|July 25, 2023
Chamelogk: A Chromatographic Chameleonicity Quantifier to Design Orally Bioavailable Beyond-Rule-of-5 DrugsDiego Garcia Jimenez, Maura Vallaro, Matteo Rossi Sebastiano, et al.
ACS Chemical Neuroscience|February 9, 2026
MK4 Repositioning for IAHSP: Overcoming In Vivo Data Gaps through In Silico Refinement and In Vitro ValidationMatteo Rossi Sebastiano, Antonio Vicidomini, Serena Francisco, et al.
Journal of Medicinal Chemistry|April 3, 2018
Impact of Dynamically Exposed Polarity on Permeability and Solubility of Chameleonic Drugs Beyond the Rule of 5Matteo Rossi Sebastiano, Bradley C Doak, Maria Backlund, et al.
European Journal of Medicinal Chemistry|February 2, 2011
An application of two MIFs-based tools (Volsurf+ and Pentacle) to binary QSAR: the case of a palinurin-related data set of non-ATP competitive glycogen synthase kinase 3β (GSK-3β) inhibitorsGiuseppe Ermondi, Giulia Caron, Isela Garcia Pintos, et al.
Dalton Transactions (Cambridge, England : 2003)|March 16, 2021
Pt(iv) complexes based on cyclohexanediamines and the histone deacetylase inhibitor 2-(2-propynyl)octanoic acid: synthesis, characterization, cell penetration properties and antitumor activityElisabetta Gabano, Beatrice Rangone, Elena Perin, et al.
Scientific Reports|November 24, 2019
Author Correction: Modeling ErbB2-p130Cas interaction to design new potential anticancer agentsAndrea Costamagna, Matteo Rossi Sebastiano, Dora Natalini, et al.
Journal of Inorganic Biochemistry|March 23, 2011
Synthesis, characterization, structure, molecular modeling studies and biological activity of sterically crowded Pt(II) complexes containing bis(imidazole) ligandsMauro Ravera, Elisabetta Gabano, Manuele Sardi, et al.
Scientific Reports|March 1, 2019
Modeling ErbB2-p130Cas interaction to design new potential anticancer agentsAndrea Costamagna, Matteo Rossi Sebastiano, Dora Natalini, et al.
ACS Omega|October 16, 2018
Conformational Sampling of Macrocyclic Drugs in Different Environments: Can We Find the Relevant Conformations?Vasanthanathan Poongavanam, Emma Danelius, Stefan Peintner, et al.
Drug Discovery Today|August 18, 2024
Preclinical alternative drug discovery programs for monogenic rare diseases. Should small molecules or gene therapy be used? The case of hereditary spastic paraplegiasMatteo Rossi Sebastiano, Shinji Hadano, Fabrizia Cesca, et al.
Pageof 10